bioAffinity Technologies News

424B3: Prospectus

Apr 17 13:06 ET

EFFECT: Others

Apr 17 06:09 ET

bioAffinity Technologies | ARS: Annual Report to Security Holders

Apr 15 06:38 ET

bioAffinity Technologies | DEF 14A: Definitive information statements

Apr 15 06:33 ET

bioAffinity Technologies | DEFA14A: Others

Apr 15 06:29 ET

bioAffinity Technologies | EFFECT: Others

Apr 8 06:07 ET

bioAffinity Technologies | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Apr 5 06:12 ET

bioAffinity Technologies | S-1: General form for registration of securities under the Securities Act of 1933

Apr 4 17:11 ET

bioAffinity Technologies | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Apr 2 17:27 ET

bioAffinity Technologies | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Apr 2 13:12 ET

bioAffinity Technologies | 10-K: Annual report

Apr 1 16:08 ET

bioAffinity Technologies | 8-K: bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Apr 1 16:04 ET

bioAffinity Technologies | 4: Statement of changes in beneficial ownership of securities-Officer GIRGENTI STEVEN

Mar 29 16:58 ET

bioAffinity Technologies | 4: Statement of changes in beneficial ownership of securities-Director Anderson Robert A.

Mar 29 16:53 ET

bioAffinity Technologies | D: Filing D

Mar 20 14:28 ET

bioAffinity Technologies | 8-K: Securities Purchase Agreement

Mar 13 16:10 ET

bioAffinity Technologies | 8-K: bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

Mar 8 17:02 ET

bioAffinity Technologies | 424B5: Prospectus

Mar 8 12:20 ET

bioAffinity Technologies | 424B5: Prospectus

Mar 8 06:05 ET

bioAffinity Technologies | 8-K: bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

Mar 5 17:28 ET